New prognostic markers and prognosis in various breast cancer subtypes

Thesis event information

Date and time of the thesis defence

Place of the thesis defence

Women's Hospital, Haartmaninkatu 2, Helsinki. Remote access: https://helsinki.zoom.us/j/6986213386?pwd=eFNNT1VMYktyUzVFZEFEdFp5VEl3QT09

Topic of the dissertation

New prognostic markers and prognosis in various breast cancer subtypes

Doctoral candidate

Licentiate of Medicine, Master of Science Nelli Roininen

Faculty and unit

University of Oulu Graduate School, Faculty of Medicine, Department of Oncology and Radiotherapy

Subject of study

Medicine

Opponent

Professor of Cancer Biology, Consulting Pathologist, Chief Executive Officer Jorma Isola, University of Tampere

Custos

Research director, docent Peeter Karihtala, HUS Comprehensive Cancer Center and University of Helsinki

Add event to calendar

Breast cancer treatment in Finland is best in the world

Breast cancer is the most common cancer among women - approximately 5 000 Finns are diagnosed with the disease yearly. In overall the prognosis of breast cancer is very good but locally advanced breast cancer is still mainly incurable. Only 50% of locally advanced breast cancer patients are alive after 5 years from the diagnosis in studied patient material of this PhD thesis. In total, 91.4% of all the breast cancer patients are alive after ten years from diagnosis.

This PhD thesis is the first Finnish study of the rare neuroendocrine breast cancers. Usually those cancers are treated the same way as the "ordinary" breast cancers, but based on this study, their biological profile is different and thus the treatment should possibly be as well. Neuroendocrine breast cancers were found to express somatostatin receptors as do some of the cancers of gastrointestinal track. Probably neuroendocrine breast cancers could be treated similarly with a drug binding to the receptor. This, nevertheless, needs more studies before the actual use of the drug.
Last updated: 7.1.2021